New therapeutic agents marketed in 1993.
In 1993, the Food and Drug Administration (FDA) approved 25 new molecular entities (NMEs), 23 of which are for therapeutic use and two are diagnostic agents. Eleven of the NMEs for therapeutic use, as well a new biological agent intended for therapeutic use, were both approved and marketed in the United States in 1993. In addition, 11 other NMEs that the FDA approved before 1993 (most in late 1992) were marketed during the year. Thus, a total of 23 therapeutic agents reached the U.S. market for the first time in 1993, a considerably lower number than the 30 new therapeutic agents marketed in 1992 and the record number 31 new agents marketed in 1991. Many of the 13 therapeutic agents approved in 1993 but not marketed before the end of the year have become available in early 1994. Of the 23 new therapeutic agents first marketed in 1993, 22 are considered in this series. The one agent not reviewed is flosequinan, which was withdrawn from the market after being available only several months because of a concern about toxicity. This review considers the new agents' most important properties and, when possible, compares them with other available agents with similar properties. When additional information is needed, more comprehensive references and the product literature should be consulted.
Hussar
D A
DA
Philadelphia College of Pharmacy and Science.
D000293:Adolescent; D000328:Adult; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D020117:Cisapride; D017338:Cladribine / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017277:Drug Approval; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D017835:Nedocromil / Q000009:adverse effects / Q000627:therapeutic use*; D009570:Nitriles; D010072:Oxamic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D014325:Tromethamine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000897:Anti-Ulcer Agents; D006634:Histamine H1 Antagonists; D009570:Nitriles; D010880:Piperidines; D014325:Tromethamine; D017835:Nedocromil; D017338:Cladribine; C022028:lodoxamide tromethamine; D017239:Paclitaxel; D010072:Oxamic Acid; D020117:Cisapride